WO2022096195A1 - Verwendung von dihydromyricetin als epigenetischer wirkstoff zur kosmetischen oder dermatologischen hautpflege - Google Patents
Verwendung von dihydromyricetin als epigenetischer wirkstoff zur kosmetischen oder dermatologischen hautpflege Download PDFInfo
- Publication number
- WO2022096195A1 WO2022096195A1 PCT/EP2021/076510 EP2021076510W WO2022096195A1 WO 2022096195 A1 WO2022096195 A1 WO 2022096195A1 EP 2021076510 W EP2021076510 W EP 2021076510W WO 2022096195 A1 WO2022096195 A1 WO 2022096195A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dihydromyricetin
- cosmetic
- epigenetic
- skin
- dna
- Prior art date
Links
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 title claims abstract description 46
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 239000002537 cosmetic Substances 0.000 title claims abstract description 17
- 230000001973 epigenetic effect Effects 0.000 title claims description 10
- 239000003795 chemical substances by application Substances 0.000 title abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 4
- 230000007420 reactivation Effects 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 239000012650 DNA demethylating agent Substances 0.000 claims 1
- 229940045805 DNA demethylating agent Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 230000011987 methylation Effects 0.000 description 10
- 238000007069 methylation reaction Methods 0.000 description 10
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000007067 DNA methylation Effects 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 229960004063 propylene glycol Drugs 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- -1 carbon alcohols Chemical class 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 4
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 4
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000008995 epigenetic change Effects 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108091029523 CpG island Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000006607 hypermethylation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical group COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LWLRMRFJCCMNML-UHFFFAOYSA-N 2-ethylhexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CC)CCCC LWLRMRFJCCMNML-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- MWKPHOIHTLQZIY-UHFFFAOYSA-N 2-hexyldecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC MWKPHOIHTLQZIY-UHFFFAOYSA-N 0.000 description 1
- RUDXBXPTJPNTSO-UHFFFAOYSA-N 2-octyldodecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC RUDXBXPTJPNTSO-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical class OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
- SJIDAAGFCNIAJP-UHFFFAOYSA-N 6-methylheptyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCC(C)C SJIDAAGFCNIAJP-UHFFFAOYSA-N 0.000 description 1
- XUVVLJKRLAXOKZ-UHFFFAOYSA-N 7-methyloctyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCC(C)C XUVVLJKRLAXOKZ-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000001582 Canarium odontophyllum Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102000009641 DNA (Cytosine-5-)-Methyltransferase 1 Human genes 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 108700005085 Switch Genes Proteins 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- BZUVPTAFNJMPEZ-CLFAGFIQSA-N [(z)-docos-13-enyl] (z)-docos-13-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCOC(=O)CCCCCCCCCCC\C=C/CCCCCCCC BZUVPTAFNJMPEZ-CLFAGFIQSA-N 0.000 description 1
- TXZRBCSUYLEATA-GALHSAGASA-N [(z)-docos-13-enyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC TXZRBCSUYLEATA-GALHSAGASA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 230000006565 epigenetic process Effects 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000014200 hypermethylation of CpG island Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- PZQSQRCNMZGWFT-QXMHVHEDSA-N propan-2-yl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(C)C PZQSQRCNMZGWFT-QXMHVHEDSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- dihydromyricetin as an epigenetic active substance for cosmetic or dermatological skin care
- the present invention relates to cosmetic or dermatological preparations containing active ingredients for the care and protection of the skin, in particular sensitive skin and, particularly, skin aged or aging due to intrinsic and/or extrinsic factors, and the use of such active ingredients and combinations such active ingredients in the field of cosmetic and dermatological skin care.
- the invention relates to the use of such agents and combinations of such agents as epigenetic agents. In particular, their use to partially or completely restore the juvenile epigenome.
- epigenetics All processes in a cell that are considered “additional" to the contents and processes of genetics are epigenetic.
- epigenetics was (first) defined as the branch of biology which studies the causal interactions between genes and their products which bring the phenotype into being Interactions between genes and their products that bring about the phenotype are examined”).
- Cosmetic skin care is primarily understood to mean that the natural function of the skin as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of endogenous substances (e.g. water, natural fats, electrolytes) strengthened or restored.
- environmental influences e.g. dirt, chemicals, microorganisms
- endogenous substances e.g. water, natural fats, electrolytes
- Another aim of skin care is to compensate for the loss of fat and water from the skin caused by daily washing. This is particularly important when the natural ability to regenerate is not sufficient.
- skin care products should protect against environmental influences, especially sun and wind, and delay skin aging.
- the chronological skin aging is z. B. caused by endogenous, genetically determined factors.
- the following structural damage and functional disorders occur in the epidermis and dermis as a result of aging, which can also come under the term "senile xerosis”: a) dryness, roughness and the formation of dryness wrinkles, b) itching and c) reduced lipid replenishment by sebaceous glands (e.g . after washing).
- Exogenous factors such as UV light and chemical noxae can have a cumulative effect and, for example, accelerate or supplement the endogenous aging processes.
- exogenous factors in particular lead to the following structural damage and functional disorders in the skin, which go beyond the extent and quality of the damage associated with chronological aging: d) Visible vascular dilation (telangiectasia, cuperosis); e) slackness and formation of wrinkles; f) local hyper-, hypo- and incorrect pigmentation (e.g. age spots) and g) increased susceptibility to mechanical stress (e.g. cracking).
- the present invention relates in particular to products for the care of naturally aged skin and for the treatment of the consequential damage of photoaging, in particular the phenomena listed under a) to g).
- Products for the care of aged skin are known per se. They contain e.g. B. retinoids (vitamin A acid and / or its derivatives) or vitamin A and / or its derivatives.
- B. retinoids vitamin A acid and / or its derivatives
- vitamin A and / or its derivatives are known per se. They contain e.g. B. retinoids (vitamin A acid and / or its derivatives) or vitamin A and / or its derivatives.
- B. retinoids vitamin A acid and / or its derivatives
- vitamin A and / or its derivatives vitamin A and / or its derivatives
- Epigenetics is a relatively young field of research in the life sciences that has attracted a lot of attention in recent years. This is not surprising, since epigenetics examines how environmental factors affect our bodies. It is less a matter of further descriptive analysis of the morphological changes described above, but rather of understanding the underlying molecular-biological regulatory mechanisms. In contrast to classical genetics, epigenetics does not deal with changes in the primary sequence of the DNA, but with the mechanisms of gene regulation. Epigenetics acts as a link between the environment and the genome.
- DNA methylation is a modification of the DNA, which in mammals usually takes place symmetrically on both DNA strands at the C5 position of cytosine nucleotides if these are located in the 5′ direction next to guanosine nucleotides (CpG) [Bird , 202],
- CpG guanosine nucleotides
- the high mutation potential of the methylated cytosine nucleotides means that the proportion of CpG dinucleotides in relation to the entire genome is very low.
- the hydrolytic deamination of the methylated cytosine leads spontaneously to the formation of thymine, resulting in TG misbase pairing.
- CpG islands CG-rich stretches of DNA in the genome. These short DNA sections are defined as 0.5-4 kb long regions whose ratio of actual to expected CG content is greater than 0.65 [Takai and Jones, 2002], about 70% of all promoters in the human genome become associated with such CpG islands [Saxonov et al., 2006], where they are usually unmethylated, which correlates with the transcriptional expression of the corresponding gene.
- CpG islands CG-rich stretches of DNA in the genome.
- Some biological processes are also known in which the methylation of a CpG island leads to the silencing of specific genes. Examples include inactivation of the X chromosome, germline and tissue specific genes [Bird, 2002, Avner and Heard, 2001, Bird, 1986], highlighting the fundamental role of DNA methylation in regulating gene expression and determining cell identity .
- the methylation can be found in regions far from the promoter, such as in repetitive sequences or in parasitic sequences, where the methylation prevents the transcription of these sequences and thus contributes to the integrity of the genome [Yoder et al., 1997, Walsh et al. , 1998], Overall, about 3 - 5% of the cytosines in the genomic DNA are methylated, which ultimately means that about 80% of the entire CpG loci of the genome are methylated [Ehrlich et al., 1982, Gama- Sosa et al., 1983],
- epigenetics is just as important for the development of a healthy organism as DNA itself.
- the scientific investigations also made it clear that the epigenome - the entirety of all epigenetic modifications - is external influences can be changed much more easily than the genes themselves.
- Epigenetically effective molecules act as mediators between the environment and genetic material. It has been clearly demonstrated that external factors can switch genes on or off and thus trigger phenotypic changes and/or diseases (Jaenisch & Bird, 2003, Bird et al. 2007; Reik, 2007; Feinberg, 2008).
- New studies have also been able to show that epigenetic changes - in particular the DNA methylation pattern - also occur during aging (Fraga et al. 2005; Esteller et al. 2012; Winnefeld & Lyko 2012).
- the substance dihydromyricetin surprisingly showed an inhibitory effect on DNA methyltransferase 1.
- This enzyme is responsible for the methylation of the CpGs in the genome and thus for maintaining the specific methylation pattern of the cell.
- the derived epigenetic activity of the active ingredient could be demonstrated in the modification of the methylation pattern in skin samples after dihydromyricetin treatment (EPIC analysis).
- EIC analysis could through the use of dihydromyricetin an increase in the expression of age-dependent hypermethylated genes can be achieved (shown for 16 genes, see Fig. 3).
- Dihydromyricetin (or (+)-dihydromyricetin; ampelopsin; (2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-4-one) is characterized by the following structure:
- JP 63316711 it is known from JP 63316711 to use dihydromyricetin as a skin lightening agent. It is also known from FR 2868701 to use dihydromyricetin as an active ingredient against cellulite, since it affects fat storage in fat cells. Furthermore, DE 10 2009 055 916 describes the use of dihydromyricetin to increase dermal collagen synthesis and to treat and prevent the symptoms of intrinsic and/or extrinsic skin aging.
- the solution to the problems on which the invention was based consists in using dihydromyricetin as a demethylating agent.
- Cosmetic or dermatological preparations according to the invention preferably contain 0.001-10% by weight, particularly preferably 0.01-1% by weight, of dihydromyricetin, based on the total composition of the preparations.
- Emulsions are advantageous forms of administration for the purposes of the present invention, e.g. B. in the form of a cream, a lotion, a cosmetic milk are advantageous and contain z.
- Medicinal topical compositions within the meaning of the present invention usually contain one or more medicaments in an effective concentration.
- the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, the following can be used as solvents:
- Oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
- Fats, waxes and other natural and synthetic fatty substances preferably esters of fatty acids with low carbon alcohols, e.g. B. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids with a low carbon number or with fatty acids;
- Alcohols, diols or polyols with a low carbon number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products.
- mixtures of the aforementioned solvents are used.
- water can also be an additional component.
- the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions in the for the purposes of the present invention, it is advantageously selected from the group of esters of saturated and/or unsaturated, branched and/or unbranched alkanecarboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and/or unsaturated, branched and/or unbranched alcohols with a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and/or unsaturated, branched and/or unbranched alcohols with a chain length of 3 to 30 carbon atoms.
- ester oils can then advantageously be selected from the group consisting of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyl decyl stearate, 2-octyldodecyl palmitate, oleyl oleate, oleyl lerucate, erucyl oleate, erucyl erucate and synthetic, semi-synthetic and natural mixtures of such esters, e.g. B. Jojoba oil.
- the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and fatty acid triglycerides, namely the triglycerol esters of saturated and/or unsaturated branched and/or unbranched alkanecarboxylic acids with a chain length of 8 to 24, in particular 12-18 carbon atoms.
- the fatty acid triglycerides can, for example, advantageously be selected from the group consisting of synthetic, semi-synthetic and natural oils, e.g. B. olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like more.
- Alcohols, diols or polyols with a low carbon number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products Alcohols with a low carbon number, e.g. B.
- ethanol isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which or which can be advantageously selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides and derivatives thereof, z.
- thickeners which or which can be advantageously selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides and derivatives thereof, z.
- B. hyaluronic acid, xanthan gum, Hydroxypropylmethylcellulose particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group of so-called Carbopols, for example Carbopol types 980, 981, 1382, 2984, 5984, each individually or in combination.
- Gels used according to the invention usually contain alcohols with a low carbon number, e.g. ethanol, isopropanol, 1,2-propanediol, glycerol and water or an above-mentioned oil in the presence of a thickener, which in the case of oily-alcoholic gels is preferably silicon dioxide or an aluminum silicate, in the case of aqueous - alcohol or alcoholic gels is preferably a polyacrylate.
- alcohols with a low carbon number e.g. ethanol, isopropanol, 1,2-propanediol, glycerol and water or an above-mentioned oil in the presence of a thickener, which in the case of oily-alcoholic gels is preferably silicon dioxide or an aluminum silicate, in the case of aqueous - alcohol or alcoholic gels is preferably a polyacrylate.
- Solid pins contain e.g. B. natural or synthetic waxes, fatty alcohols or fatty acid esters.
- Common base materials which are suitable for use as cosmetic sticks in the context of the present invention are liquid oils (e.g. paraffin oils, castor oil, isopropyl myristate), semi-solid components (e.g. vaseline, lanolin), solid components (e.g. beeswax , ceresin and microcrystalline waxes or ozokerite) as well as high-melting waxes (e.g. carnauba wax, candelilla wax).
- liquid oils e.g. paraffin oils, castor oil, isopropyl myristate
- semi-solid components e.g. vaseline, lanolin
- solid components e.g. beeswax , ceresin and microcrystalline waxes or ozokerite
- high-melting waxes e.g. carnauba wax, candelilla wax
- Suitable propellants for cosmetic and/or dermatological preparations that can be sprayed from aerosol containers according to the present invention are the customary, readily volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or mixed with one another. Compressed air is also advantageous to use.
- DNMT1 DNA methyltransferase 1
- DNMT Activity/Inhibition Assay Active Motif, Belgium
- the concentration-dependent inhibition of the recombinant DNMT1 enzyme could be shown (Fig. 1).
- the assay manufacturer's standard protocol was used.
- the verum-treated area showed methylation changes in 16,389 CpGs compared to the non-irradiated control, whereas the vehicle-treated area showed no significant methylation changes. It was thus possible to prove that dihydromyricetin is an epigenetic modulator (Fig. 2).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021373926A AU2021373926A1 (en) | 2020-11-06 | 2021-09-27 | Use of dihydromyricetin as epigenetic cosmetic or dermatological skin care agent |
EP21782561.1A EP4255383A1 (de) | 2020-11-06 | 2021-09-27 | Verwendung von dihydromyricetin als epigenetischer wirkstoff zur kosmetischen oder dermatologischen hautpflege |
US18/035,346 US20230414555A1 (en) | 2020-11-06 | 2021-09-27 | Use of dihydromyricetin as epigenetic active ingredient for cosmetic or dermatological skin care |
CN202180074845.3A CN116456960A (zh) | 2020-11-06 | 2021-09-27 | 二氢杨梅素作为表观遗传活性物质用于化妆性皮肤护理或皮肤病学皮肤护理的用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102020213959.8 | 2020-11-06 | ||
DE102020213959.8A DE102020213959A1 (de) | 2020-11-06 | 2020-11-06 | Verwendung von Dihydromyricetin als epigenetischer Wirkstoff zur kosmetischen oder dermatologischen Hautpflege |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022096195A1 true WO2022096195A1 (de) | 2022-05-12 |
Family
ID=77989835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/076510 WO2022096195A1 (de) | 2020-11-06 | 2021-09-27 | Verwendung von dihydromyricetin als epigenetischer wirkstoff zur kosmetischen oder dermatologischen hautpflege |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230414555A1 (de) |
EP (1) | EP4255383A1 (de) |
CN (1) | CN116456960A (de) |
AU (1) | AU2021373926A1 (de) |
DE (1) | DE102020213959A1 (de) |
WO (1) | WO2022096195A1 (de) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2356980A2 (de) * | 2009-11-27 | 2011-08-17 | Beiersdorf Ag | Verwendung von Dihydromyricetin gegen Altershaut |
WO2014012075A2 (en) * | 2012-07-13 | 2014-01-16 | Phyto Tech Corp. | Compositions and methods for treating hair loss and delaying aging of skin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63316711A (ja) | 1987-06-17 | 1988-12-26 | Nonogawa Shoji:Kk | 美白化粧料 |
ES2241491B1 (es) | 2004-04-07 | 2006-12-01 | Provital, S.A. | Composicion cosmetica y/o farmaceutica, reguladora de los niveles de grasa en adipocitos y/o reguladora de la diferenciacion adipocitaria. |
-
2020
- 2020-11-06 DE DE102020213959.8A patent/DE102020213959A1/de active Pending
-
2021
- 2021-09-27 US US18/035,346 patent/US20230414555A1/en active Pending
- 2021-09-27 WO PCT/EP2021/076510 patent/WO2022096195A1/de active Application Filing
- 2021-09-27 EP EP21782561.1A patent/EP4255383A1/de active Pending
- 2021-09-27 CN CN202180074845.3A patent/CN116456960A/zh active Pending
- 2021-09-27 AU AU2021373926A patent/AU2021373926A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2356980A2 (de) * | 2009-11-27 | 2011-08-17 | Beiersdorf Ag | Verwendung von Dihydromyricetin gegen Altershaut |
WO2014012075A2 (en) * | 2012-07-13 | 2014-01-16 | Phyto Tech Corp. | Compositions and methods for treating hair loss and delaying aging of skin |
Also Published As
Publication number | Publication date |
---|---|
AU2021373926A9 (en) | 2023-09-07 |
US20230414555A1 (en) | 2023-12-28 |
CN116456960A (zh) | 2023-07-18 |
DE102020213959A1 (de) | 2022-05-12 |
EP4255383A1 (de) | 2023-10-11 |
AU2021373926A1 (en) | 2023-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69811263T2 (de) | Konjugierte linolsäure enthaltendes verteilungssystem in kosmetika | |
DE60313597T2 (de) | Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis | |
DE69831269T2 (de) | Behandlung von narbengewebe mit liponsäure | |
DE102009059220A1 (de) | Kosmetische Zusammensetzung, die wenigstens zwei Osmolyten mit hydratisierender oder altershemmender Wirkung enthält | |
EP1569724B1 (de) | Formulierungen enthaltend melatonin, ginkgo biloba und biotin | |
JPH05186324A (ja) | 美白化粧料 | |
EP0596284A2 (de) | Antimycotische kosmetische und dermatologische Zubereitungen mit einem Gehalt an Fettsäureestern | |
CN110769817A (zh) | 皮肤治疗方法、含类视黄醇的组合物及其递送系统 | |
DE69525539T2 (de) | Verwendung von 2,4-diaminopyrimidin-3-oxyd und/oder seine salze zur behandlungvon störungen der kollagenreifung oder -strukturierung | |
DE102005022625A1 (de) | Verwendung von Taurin zur Steigerung der epidermalen Lipidsynthese | |
DE60214207T2 (de) | Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis | |
WO2022096195A1 (de) | Verwendung von dihydromyricetin als epigenetischer wirkstoff zur kosmetischen oder dermatologischen hautpflege | |
DE69824910T2 (de) | Andiroba Extrakt enthaltende kosmetische oder pharmazeutische Zusammensetzung | |
WO2014040826A2 (de) | Verwendung von 4–(4–hydroxyphenyl)–2–butanon als demethylierendes agens | |
CN110996897A (zh) | 含有神经酰胺、其衍生物以及木槿皮提取物的皮肤外用剂组合物 | |
EP1667641A1 (de) | Kosmetische oder dermatologische zubereitungen mit einem gehalt an isoflavonen und licochalcon a | |
WO2002092029A2 (de) | Kosmetische und dermatologische zubereitung zur beseitigung und regulation von sebum | |
DE102011089558A1 (de) | Neue Verwendungen von Trimethylglycin und Harnstoffderivaten | |
KR102084415B1 (ko) | 에피피노레시놀을 포함하는 화장료 조성물 | |
US11986544B2 (en) | Application for inhibitors of cAMP efflux in body care | |
WO2018099675A1 (de) | Verwendung von 2'-methoxyflavon in kosmetischen oder dermatologischen zubereitungen zur prophylaxe vor und behandlung von sensibler haut | |
DE102016225095B4 (de) | "Kosmetische Gesichtspflegeformulierungen zur Stimulierung der körpereigenen Abwehr gegen freie Radikale" | |
DE102011085586A1 (de) | Verwendung von Zingeron zur verbesserten Hautkonturierung bzw. gegen Cellulite | |
EP2589374B1 (de) | Verwendung von Magnolienrindenextrakt zur Verbesserung der Hautoberflächenstruktur und zur Verminderung von Cellulite | |
FR3010633A1 (fr) | Actif complexe d'origine marine a effet antioxydant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21782561 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18035346 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180074845.3 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023008573 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021782561 Country of ref document: EP Effective date: 20230606 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112023008573 Country of ref document: BR Free format text: APRESENTE O RELATORIO DESCRITIVO COM A NUMERACAO DAS PAGINAS CORRIGIDA. |
|
ENP | Entry into the national phase |
Ref document number: 2021373926 Country of ref document: AU Date of ref document: 20210927 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112023008573 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230504 |